Published in Trends Immunol on January 02, 2007
Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 3.35
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol (2013) 2.29
Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res (2009) 1.86
Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc Natl Acad Sci U S A (2010) 1.79
Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies? Immunology (2009) 1.64
Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system. Clin Cancer Res (2011) 1.24
The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells. Mol Cancer (2013) 1.19
Lupus nephritis: lessons from murine models. Nat Rev Rheumatol (2009) 1.18
Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. Blood (2009) 1.10
Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One (2009) 1.10
Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology (2008) 1.09
T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J Clin Invest (2013) 1.06
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets (2009) 1.01
Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NFκB pathway. Transl Psychiatry (2012) 0.99
Functional aspects of Toll-like receptor/MyD88 signalling during protozoan infection: focus on Toxoplasma gondii. Clin Exp Immunol (2009) 0.96
Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci (2010) 0.95
Blimp-1/PRDM1 mediates transcriptional suppression of the NLR gene NLRP12/Monarch-1. J Immunol (2009) 0.93
Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome. PLoS One (2011) 0.89
Toll-like receptor 3 (TLR3) protects retinal pigmented epithelium (RPE) cells from oxidative stress through a STAT3-dependent mechanism. Mol Immunol (2012) 0.86
A Distinct Profile of Tryptophan Metabolism along the Kynurenine Pathway Downstream of Toll-Like Receptor Activation in Irritable Bowel Syndrome. Front Pharmacol (2012) 0.85
Activated natural killer T cells producing interferon-gamma elicit promoting activity to murine dendritic cell-based autoimmune hepatic inflammation. Clin Exp Immunol (2012) 0.83
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest (2015) 0.81
TLR and NKG2D signaling pathways mediate CS-induced pulmonary pathologies. PLoS One (2013) 0.80
Activation of Toll-like receptor 9 attenuates unilateral ureteral obstruction-induced renal fibrosis. Acta Pharmacol Sin (2010) 0.79
Susceptibility to ankylosing spondylitis: evidence for the role of ERAP1, TGFb1 and TLR9 gene polymorphisms. Rheumatol Int (2011) 0.78
Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists. Cancer Gene Ther (2011) 0.78
Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication. J Virol (2015) 0.78
Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases. Int J Mol Sci (2016) 0.77
Toll-like receptors 4 and 9 are responsible for the maintenance of the inflammatory reaction in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. J Neuroinflammation (2012) 0.77
Common variable immunodeficiency: etiological and treatment issues. Int Arch Allergy Immunol (2009) 0.77
Inhibitory short synthetic oligodeoxynucleotides and lupus. Arthritis Res Ther (2009) 0.76
In vitro inflammation inhibition model based on semi-continuous toll-like receptor biosensing. PLoS One (2014) 0.76
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 4.22
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 3.80
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A (2008) 3.55
Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol (2008) 3.05
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63
Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med (2002) 2.54
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med (2006) 2.44
Fc-receptors as regulators of immunity. Adv Immunol (2007) 2.38
Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J Exp Med (2003) 2.23
Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A (2005) 2.22
Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 2.20
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 2.10
Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med (2006) 2.00
The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol (2004) 1.95
Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A (2006) 1.91
Antibodies, Fc receptors and cancer. Curr Opin Immunol (2007) 1.89
Antibody-mediated modulation of immune responses. Immunol Rev (2010) 1.84
A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol (2010) 1.84
The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med (2007) 1.84
Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science (2005) 1.81
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81
Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med (2002) 1.77
General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A (2013) 1.69
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A (2007) 1.66
Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A (2012) 1.62
Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood (2005) 1.55
Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. J Exp Med (2007) 1.53
FcγRs in health and disease. Curr Top Microbiol Immunol (2011) 1.51
Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med (2007) 1.51
Novel roles for the IgG Fc glycan. Ann N Y Acad Sci (2012) 1.51
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A (2010) 1.46
In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A (2008) 1.44
Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol (2007) 1.32
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A (2008) 1.31
A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A (2012) 1.23
Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity (2002) 1.19
Analyzing antibody-Fc-receptor interactions. Methods Mol Biol (2008) 1.19
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest (2016) 1.12
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci U S A (2012) 1.11
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res (2003) 1.11
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med (2010) 1.10
Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol (2008) 1.08
Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res (2002) 1.08
Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun (2012) 1.05
Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol (2008) 1.04
FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J Immunol (2008) 1.03
Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum (2009) 1.00
Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol (2008) 1.00
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood (2003) 0.96
Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc Natl Acad Sci U S A (2013) 0.96
Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest (2014) 0.95
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle (2012) 0.94
Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res (2004) 0.94
New nomenclature for Fc receptor-like molecules. Nat Immunol (2006) 0.94
Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice. J Exp Med (2005) 0.93
Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. Am J Pathol (2003) 0.92
Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. J Immunol (2011) 0.86
Inhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms. J Immunol (2014) 0.85
Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. Proc Natl Acad Sci U S A (2013) 0.85
Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol (2013) 0.84
A critical role for Fc gamma RIIB in the induction of rheumatoid factors. J Immunol (2004) 0.82
humanized mice to study FcγR function. Curr Top Microbiol Immunol (2014) 0.81
Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease. Am J Pathol (2007) 0.81
Reply to Crispin et al.: Molecular model that accounts for the biological and physical properties of sialylated Fc. Proc Natl Acad Sci U S A (2013) 0.81
Killing some to make way for others. Nat Immunol (2007) 0.79
The Role and Function of Fcγ Receptors on Myeloid Cells. Microbiol Spectr (2016) 0.75
Closing the circle. Jeffrey V. Ravetch, M.D., Ph.D. Interviewed by Lynne Lederman. Biotechniques (2008) 0.75
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell (2015) 0.75